Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06369285
Title A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)
Acronym ALISCA-Breast1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Puma Biotechnology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Alabama Oncology RECRUITING Birmingham Alabama 34235 United States Details
Mayo Clinic Hospital RECRUITING Phoenix Arizona 85054 United States Details
LA Cancer Network RECRUITING Los Angeles California 90017 United States Details
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center RECRUITING San Francisco California 94158 United States Details
Yale University, Yale Cancer Center RECRUITING New Haven Connecticut 06520 United States Details
Mayo Clinic Florida RECRUITING Jacksonville Florida 32224 United States Details
Mayo Clinic RECRUITING Rochester Minnesota 55905 United States Details
Taylor Cancer Research Center RECRUITING Maumee Ohio 43537 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field